CO.DON is science-driven biopharmaceutical company committed to research, development and commercialisation of autologous cell therapies for the repair of cartilage defects. Our products use only the patientÕs own cells and blood, is additive-free and the procedure is minimally invasive. Currently, over 11,000 patients have been treated in 200 clinics in Germany. In July 2017 we received marketing authorisation for an advanced therapy medicinal product from the European Medicine Agency. CO.DON is listed on the Frankfurt Stock Exchange. (ISIN: DE000A1K0227).